The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel

Table 2 Frequencies of clopidogrel resistance in subgroups

		VASP-PRI Resistant (n = 45)	p-value¹	VerifyNow-PRU Resistant (n = 67)	p-value²
Diabetes	Yes	8 (31%)		14 (45%)
	No	37 (29%)	.831	53 (29%)	.079
Smoking	Yes	7 (29%)		10 (30%)
	No	38 (29%)	.987	57 (32%)	.861
Hypertension	Yes	27 (29%)		42 (35%)
	No	18 (29%)	1.000	25 (27%)	.262
Previous MI	Yes	19 (33%)		34 (43%)
	No	26 (27%)	.429	33 (25%)	.006
Statins	Yes	44 (29%)		63 (30%)
	No	1 (25%)	.857	4 (80%)	.180
CCBs	Yes	10 (30%)		21 (45%)
	No	35 (29%)	.856	46 (28%)	.031
PPIs	Yes	9 (43%)		7 (26%)
	No	36 (27%)	.440	60 (32%)	.665
BMI≥27 (kg/m2)	Yes	29 (35%)		43 (39%)
	No	16 (22%)	.082	24 (24%)	.015

Frequencies of clopidogrel resistance in subgroups, evaluated by VASP-PRI (n = 45 of 155) and VerifyNow-PRU (n = 67 of 212). Numbers (proportions) are given.
Abbreviations: MI (myocardial infarction), CCB (calcium channel blockers), PPI (proton pump inhibitors), BMI (body-mass index).
p¹-values refer to differences in subgroups assessed by the VASP-method, and p²-values refer to differences in subgroups assessed by the VerifyNow-method.

ISSN: 1477-9560